12:18 PM EST - Revive Therapeutics Ltd : Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Revive Therapeutics Ltd
shares C.RVV are trading up $0.08 at $0.30.
